Sarmad Zahoor

Sarmad Zahoor

Auto-generated profile, based on publicly available information

Sarmad Zahoor

Punjab Institute of Cardiology, Lahore, Pakistan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2022 in Cureus
Verified
Journal Article
Open access
SKSarfaraz Khan
Sarfaraz Khan
MHMubashar Sultan Hashmi
Mubashar Sultan Hashmi
MRMuhammad Asim Rana
Muhammad Asim Rana
GZGhulam Mujtaba Zafar
Ghulam Mujtaba Zafar
SASadia Asif
Sadia Asif
SZSarmad Zahoor
Sarmad Zahoor
Urinary tract infections (UTIs) are common in patients with diabetes. The use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) to achieve good glycemic control increases glucose levels in urine. This glycosuria further enhances the risk of UTIs. This study aimed to evaluate the frequency of UTIs in patients with type 2 diabetes receiving the SGLT2i dapagliflozin as an add-on therapy. We conducted this cross-sectional study at the Endocrinology Department of Hayatabad Medical Complex in Peshawar from April 2020 to September 2020. A total of 400 patients with diabetes receiving either 5 mg or 10 mg of dapagliflozin as an add-on therapy for the treatment of type 2 diabetes were included in this study. We collected blood and urine samples from participants and measured glycosylated hemoglobin levels. Urine samples were cultured on cysteine lactose electrolyte deficient agar. We used IBM SPSS Statistics for Windows, version 25.0 (IBM Corp., Armonk, NY) to analyze our data. The prevalence of UTIs in diabetic patients receiving 5 mg or 10 mg of dapagliflozin was 5.3%. Women were more affected (76.2%) than men (p < 0.05). UTIs were more prevalent in patients older than 50 years (85.7%) than in any other age group. The dose strength of dapagliflozin was not associated with UTIs (p > 0.05). This study examined UTIs in patients taking dapagliflozin for the treatment of type 2 diabetes. These infections were mild to moderate and were treated easily. None of these infections caused the patient to discontinue the treatment. Dapagliflozin is well-tolerated in patients with diabetes but should be used with appropriate caution and monitoring.

28 August 2021 in Cureus
Verified
Journal Article
Open access
SZSarmad Zahoor
Sarmad Zahoor
AKAleena Khan
Aleena Khan
SASadia Asif
Sadia Asif
STSair Ahmad Tabraiz
Sair Ahmad Tabraiz
HMHossam Mustafa
Hossam Mustafa
HRHassan Ali Raza
Hassan Ali Raza
Hepatitis B and C are viral infections of the liver transmitted by blood contamination. These infections are endemic in Pakistan and put a tremendous burden on its healthcare system. We conducted this study to assess the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in Gujranwala, Pakistan, from 2010 to 2015 and determine the trend of future infections for a prediction of the disease burden by 2030 so policymakers can make informed decisions. We conducted a retrospective cross-sectional study of 66,308 healthy blood donor samples at District Headquarters Teaching Hospital in Gujranwala from January 2010 to December 2015. Samples were screened for HBV and HCV using the kit method, and data were analyzed using IBM SPSS Statistics for Windows, version 20.0 (IBM Corp., Armonk, NY). We applied a least squares regression to our results to predict HBV and HCV incidence in 2030. A total of 715 samples (1.08%) were positive for HBV and 1,846 samples (2.78%) were positive for HCV. Our projections indicate that 3.25% of patients in Pakistan will be positive for HBV, and 6.36% will be positive for HBC by 2030. We found an unexpectedly greater burden of HBV and HCV in the recent past than at current levels. The predicted percentages of future burden over the next decade were alarmingly high. These data necessitate implementing preventive and therapeutic measures by policymakers to reduce the disease burden and mortality in Pakistan.

1 October 2022 in Reumatología Clínica
Verified
Journal Article
Closed access
SASadia Asif
Sadia Asif
AKAsadullah Khan
Asadullah Khan
SZSarmad Zahoor
Sarmad Zahoor
NLNaveed Lashari
Naveed Lashari
MHMuhammad Haroon
Muhammad Haroon
AKAfshan Khanum
Afshan Khanum

27 April 2022 in The Lancet Oncology
Verified
Journal Article
Closed access
UAUsman Ayub Awan
Usman Ayub Awan
MMMuhammad Wasif Malik
Muhammad Wasif Malik
MAMuhammad Sohail Afzal
Muhammad Sohail Afzal
HAHaroon Ahmed
Haroon Ahmed
SZSarmad Zahoor
Sarmad Zahoor

31 December 2021 in Archives of Rheumatology
Verified
Journal Article
Open access
PDF file
SASadia Asif
Sadia Asif
AKAsadullah Khan
Asadullah Khan
MFMuhammad Faiq
Muhammad Faiq
ZDZia Ud Din
Zia Ud Din
SZSarmad Zahoor
Sarmad Zahoor
MHMuhammad Haroon
Muhammad Haroon
Objectives: This study aims to evaluate the clinical and serological characteristics of systemic sclerosis (SSc) in Pakistani population. Patients and methods: This prospective, cross-sectional study included a total of 38 patients (6 males, 32 females; mean age: 34.5±1.5 years; range, 16 to 60 years) with SSc who were admitted to our rheumatology clinic between November 2019 and January 2020. We evaluated the clinical, serological, and radiological features of SSc patients. Results: Thirty-four (89.5%) patients developed Raynaud phenomenon at the time of disease onset, while sclerodactyly was found in 34 (89.5%), digital ulcers in 25 (65.8%), and tendon friction rub in 12 (31.6%) patients. Interstitial lung disease was present in 30 (78.9%) patients with a higher prevalence in diffuse scleroderma (100%) than in limited scleroderma (70%) (p=0.01). Pulmonary hypertension was present in 18 patients with a significantly higher prevalence in diffuse disease (57.1%) than limited disease (11.8%) (p

26 April 2022 in Neurosciences
Verified
Journal Article
Open access
PDF file
YAYassir M. Almatrafi
Yassir M. Almatrafi
MBMohammed A. Babakkor
Mohammed A. Babakkor
MIMuhammed Irfan
Muhammed Irfan
ESEbaa T. Samkari
Ebaa T. Samkari
WAWaleed M. Alzahrani
Waleed M. Alzahrani
HJHafiz M. Sajid Jehangir
Hafiz M. Sajid Jehangir
Objectives: To assess the efficacy and safety of rituximab for multiple sclerosis (MS) treatment in terms of reduction in clinical relapses, magnetic resonance imaging (MRI) activity, Expanded Disability Status Scale (EDSS) score and adverse events. Methods: This is a retrospective cross-sectional study conducted at King Abdullah Medical City, from January 2017 to August 2021, involving patients with MS given rituximab, with 1-year follow-up. Clinical parameters were noted pre- and post-treatment to determine efficacy; adverse events were noted to analyze safety. A paired samples t-test was used to compare responses pre- and post-treatment. A p-value<0.05 was considered significant. Results: Among 31 patients, 6 (19.4%) had progressive MS, and 25 (80.6%) had relapsing-remitting MS (mean disease duration=8.12±5.65 years). The annual relapse rate reduced from 1.67±0.97 to 0.06±0.25 (p<0.001), the EDSS score from 3.16±2.14 to 2.80±2.28 (p=0.141) and the MRI activity score from 1.84±1.03 to 1.03±0.18 (p<0.001). Only one patient had enhancing lesion activity post-treatment. The commonest side effect was urinary tract infection (25.8%). Only 2 patients discontinued the drug. Conclusion: Rituximab is an efficient drug in reducing the annual relapse rate and MRI activity of patients with MS, with few tolerable side effects not leading to drug discontinuation or any lethal outcome.